Post by Malick PAYE

I am extremely proud to announce that D&A MedLabs is now entering the commercialization phase, with our services available through 𝗕𝗶𝗼𝗣𝗮𝘁𝗵 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺, our healthcare 𝗱𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗶𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝗰𝗲 𝗹𝗮𝘆𝗲𝗿! Built on one of the most comprehensive biomedical knowledge graphs available in the market with more than 100+ entities and 1.000+ relation types, BioPath integrates: ▪️ 400M+ scientific documents ▪️ 17K biological targets ▪️ 2.9M compounds ▪️ 127M patents ▪️ 600K clinical trials ▪️ 8.5M genomic profiles ▪️ 1M+ curated news ▪️ 15+ years of claims data (US) ▪️ 20+ years of adverse events   Covering more than 𝟱.𝟬𝟬𝟬 clinical conditions and 𝟯𝟬.𝟬𝟬𝟬+ molecular biomarkers. BioPath is not another drug discovery AI platform. Most AI platforms generate insights, but the real challenge today is turning complex, fragmented evidence into clear and reliable decisions. That’s why we position BioPath as a decision intelligence layer. We have structured BioPath around five core high value services: 1️⃣ 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺 𝗘𝗹𝘂𝗰𝗶𝗱𝗮𝘁𝗶𝗼𝗻 Understand biological mechanisms behind each of the 5.000 clinical conditions with fully traceable evidence using graph algorithms. 2️⃣ 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗗𝗿𝗶𝘃𝗲𝗿 𝗣𝗿𝗶𝗼𝗿𝗶𝘁𝗶𝘇𝗮𝘁𝗶𝗼𝗻 Leverage a decision framework to identify and prioritize the most impactful biomarkers across 5.000+ clinical conditions and a pool of 30.000+ candidate biomarkers. 3️⃣ 𝗧𝗵𝗲𝗿𝗮𝗽𝗲𝘂𝘁𝗶𝗰 𝗢𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗘𝘅𝗽𝗹𝗼𝗿𝗮𝘁𝗶𝗼𝗻 Analyze ongoing and completed trials, with unique enriched strategic information provided by our proprietary clinical trial probability-of-success algorithm. 4️⃣ 𝗗𝗿𝘂𝗴 𝗥𝗲𝗽𝘂𝗿𝗽𝗼𝘀𝗶𝗻𝗴 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗲𝘀 Prioritize potential new indications for each of 2.000+ approved drugs based on biological and clinical signals integrated into our repurposing score. 5️⃣ 𝗔𝗱𝘃𝗲𝗿𝘀𝗲 𝗘𝘃𝗲𝗻𝘁 𝗠𝗲𝗰𝗵𝗮𝗻𝗶𝘀𝗺𝘀 𝗜𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻 Infer underlying biological mechanisms behind side effects observed in real-world data to uncover novel insights and better understand treatment responses using our hypothesis generation algorithm. What makes BioPath unique is not only the amount of integrated data. It’s the ability to structure all these dimensions into a coherent, transparent, and scientifically grounded decision framework. Visit our website 👉 https://lnkd.in/e7fFc7GN, book a demo, or even better, join our ongoing pilot! Lyonbiopôle Auvergne-Rhône-Alpes Mze Ali Housni Emmanuel DEJEAN Bruno VIRIEUX Simon Baconnier Fabrice Romano 🚀 Bruno Privat Eric Cheminot BIO M. TOKO WOROU (Ph. D) Frederic REYNIER Marie-Angélique Cazalis Julien Marchand Alex Nkengne, PhD Ibrahima PAYE Messalia Beghri Dr. Ibrahima Socé Fall Dominique MARC Pierre Mahé Belen Moscoso del Prado, Lopez-Doriga Eloy Sasot Youssef B. Idelcaid Samir Salah Dr Delphine Kerob Wilfried YENOUSSI Alexandre Merieux Géraud van Gaver Bruno Lacroix